Holen Sie sich die Stockscreener-App
2.36
2.78%
0.07
Handel nachbörslich:
2.32
-0.04
-1.69%
Schlusskurs vom Vortag:
$2.29
Offen:
$2.24
24-Stunden-Volumen:
448.21K
Relative Volume:
0.84
Marktkapitalisierung:
$132.81M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
236.00
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
+8.96%
1M Leistung:
+23.87%
6M Leistung:
+235.75%
1J Leistung:
+91.35%
1-Tages-Spanne:
$2.24
$2.385
1-Wochen-Bereich:
$2.18
$2.42
52-Wochen-Spanne:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Vergleichen Sie SPRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.36 | 128.87M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
How strong is Spero Therapeutics Inc. stock revenue growth2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - newser.com
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewswire
What does recent volatility data suggest for Spero Therapeutics Inc.Market Trend Summary & High Accuracy Investment Signals - newser.com
What MACD signals say about Spero Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com
Forecasting Spero Therapeutics Inc. price range with options dataWeekly Trend Report & Entry Point Strategy Guides - newser.com
Is Spero Therapeutics Inc a good long term investmentTechnology Stock Trends & Free Stock Index Interpretations - earlytimes.in
Is Spero Therapeutics Inc. (2HA) stock positioned for digital growth eraMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com
Key resistance and support levels for Spero Therapeutics Inc.Portfolio Gains Report & Stock Timing and Entry Methods - newser.com
Sector ETF performance correlation with Spero Therapeutics Inc.July 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Best Momentum Stock to Buy for October 10th - sharewise.com
Spero Therapeutics' (SPRO) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What analysts say about Spero Therapeutics Inc stockSell Signals and Alerts & Breakthrough Investment Results - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
October 2025's Promising Penny Stocks To Consider - simplywall.st
Key metrics from Spero Therapeutics Inc.’s quarterly dataWall Street Watch & Low Risk High Reward Ideas - newser.com
Heatmap analysis for Spero Therapeutics Inc. and competitors2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
Is Spero Therapeutics Inc. (2HA) stock safe for risk averse investors2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Will Spero Therapeutics Inc. see short term momentumTrade Analysis Report & Daily Volume Surge Signals - newser.com
Spero Therapeutics CEO sells shares worth $121,159 - MSN
Spero Therapeutics Inc. stock trend forecastJuly 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):